Galenea Corporation is focused on developing drugs that treat neurodegenerative central neurvous system (CNS) diseases via the modulation of synaptic transmission: the process by which neurons communicate. The company uses an integrated drug discovery approach that utilizes its proprietary Multiwell Automated NeuroTRansmission Assay (MANTA) synaptic screening technology for primary neurons and neurons developed from human stem cells. The company is also focused on preclinical network measures based on MANTRA screening and is developing clinical biomarkers based on brain activity in humans as measured by electroencephalogram (EEG) for use in clinical development. Intitially based on research on the role of calcineurin in the pathogenisis of schizophrenia, the companny's discovery platform also generated a therapeutics program for cognitive impairment, and discovery programs in Huntington's disease and neurodegeneration.
